Treatment of advanced cystic fibrosis lung disease and end of life decisions

J.S. Elborn (Belfast, United Kingdom)

Source: School Course 2013 - Cystic Fibrosis

Number: 10

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J.S. Elborn (Belfast, United Kingdom). Treatment of advanced cystic fibrosis lung disease and end of life decisions. School Course 2013 - Cystic Fibrosis

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Treatment of advanced CF lung disease and end of life care Source: ERS course 2015 Year: 2015
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021
Patient reported quality of life in advanced cystic fibrosis (CF) lung disease assessed for lung transplantation Source: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous Year: 2008
Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014
Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014
Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019
Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020
Relations between the sinonasal development and the lung disease in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 103s Year: 2005
Tracking disease progression in cystic fibrosis using bronchiectasis, trapped air and quality of life Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research Year: 2012
Elucidating progression of early cystic fibrosis lung disease Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017 Year: 2017
The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020
Non invasive ventilation for advanced cystic fibrosis lung disease in children Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011
Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020
Antibiotic treatment of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 188-202 Year: 2014
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015